Show simple item record

dc.contributor.authorRembeck, Karolinaen_US
dc.contributor.authorMaglio, Cristinaen_US
dc.contributor.authorLagging, Martinen_US
dc.contributor.authorChristensen, Peer Brehmen_US
dc.contributor.authorFärkkilä, Marttien_US
dc.contributor.authorLangeland, Ninaen_US
dc.contributor.authorMørch, Kristineen_US
dc.contributor.authorBuhl, Mads R.en_US
dc.contributor.authorPedersen, Courten_US
dc.contributor.authorNorkrans, Gunnaren_US
dc.contributor.authorHellstrand, Kristofferen_US
dc.contributor.authorLindh, Magnusen_US
dc.contributor.authorPirazzi, Carloen_US
dc.contributor.authorBurza, Maria A.en_US
dc.contributor.authorRomeo, Stefanoen_US
dc.contributor.authorWestin, Johanen_US
dc.contributor.authorfor the NORDynamIC groupen_US
dc.PublishedBMC Medical Genetics 2012, 13:82eng
dc.description.abstractBackground: Hepatic steatosis in HCV patients has been postulated as a risk factor associated with a higher frequency of fibrosis and cirrhosis. A single genetic variant, PNPLA3 I148M, has been widely associated with increased hepatic steatosis. Previous studies of the PNPLA3 I148M sequence variant in HCV infected individuals have reported an association between this variant and prevalence of steatosis, fibrosis, and cirrhosis. To evaluate the impact of PNPLA3 I148M variant on metabolic traits and treatment response in HCV genotype 2 and 3 infected patients. Methods. Three hundred and eighty-two treatment naïve HCV genotype 2 or 3 infected patients were included in a phase III, open label, randomized, multicenter, investigator-initiated trial (the NORDynamIC study), in which pretreatment liver biopsies were mandatory. PNPLA3I148M genotyping was performed in a total of 359 Caucasian patients. Results: In HCV genotype 2 infected patients carrying the PNPLA3 148M allele, there was significantly increased insulin resistance (P = 0.023) and lower viral load (P = 0.005) at baseline as well as the first seven days of antiviral treatment. These results were not observed in HCV genotype 3 infected patients. Conclusions: Our results suggest a possible association between the PNPLA3 148M allele and insulin resistance as well as baseline viral load in HCV genotype 2, but not in genotype 3.en_US
dc.publisherBioMed Centraleng
dc.rightsAttribution CC BYeng
dc.subjectHepatitis Ceng
dc.subjectInsulin resistanceeng
dc.subjectViral loadeng
dc.titlePNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infectionen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2012 Rembeck et al.; licensee BioMed Central Ltd.
dc.source.journalBMC Medical Genetics

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY